We are committed to conducting research studies in an effort to find cures and treatments for the most common, debilitating and troubling diseases. Currently more than 2,000 research studies are being conducted across the North Shore-LIJ Health System and 15,000 participants are enrolled in studies annually. These research studies help determine the safety and effectiveness of medications, devices, diagnostic products, and treatment regimens for these diseases.
See the search feature below to find research studies that are currently being conducted. You might even want to participate in a study to potentially find ways to provide better future care for yourself or others. (Please note that we are in the process of including additional studies into this search feature, so check back often.)
For more information about research studies, please click here, or call 1-877-GO-NSLIJ (1-877-466-7545).
The Feinstein Institute prioritizes the well being of patients. To learn more about the patient’s rights and responsibilities, click here.
Found 222 results matching your search criteria
The purpose of this study is to find out the best way to treat older adults with wrist fractures. Distal radius (wrist) fractures can be treated either without surgery or with surgery. Without surgery, a splint or a cast is placed on the wrist and will remain until a fracture is healed, usually 6 to 8 weeks. One is able to perform most everyday activities with the cast or splint on. There are three common ways to surgically manage distal radius (wrist) fractures with surgical fixation: Percutaneous Pinning, External Fixation and Internal Fixation.
This research is being done to find out what effects, good and/or bad, that anastrozole has on patients, and whether their genes can help explain how the study drug, anastrozole, affects them. Specifically, many women who take anastrozole, or one of the other aromatase inhibitors (letrozole or exemestane) during treatment for breast cancer, report muscle and joint aches; however, the reasons that lead to these symptoms are not known. Small studies have suggested that a person’s genetic information may help us to develop a way to predict who will develop side effects and how best to treat them, and we hope to collect information in this study to look at this more closely. In addition, we hope to look at how the side effects from hormone therapy influence quality of life and a patient’s willingness to continue hormonal treatment.
This study is considered research because the study drug, regorafenib, is under development and has not yet been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer when given in combination with FOLFIRI chemotherapy. FOLFIRI is the name of a group of chemotherapy drugs that include 5-Fluorouracil (5-FU), leucovorin and irinotecan, and is standard of care for this type of cancer.
In this study, patients will be assigned to receive either regorafenib plus standard of care chemotherapy (FOLFIRI) or placebo plus standard of care chemotherapy (FOLFIR). The purpose of this study is to assess whether the combination of regorafenib with FOLFIRI chemotherapy will result in increased survival without the cancer getting worse as compared to receiving FOLFIRI chemotherapy alone.
The primary purposes of this study are to provide access to cord blood units for recipients whose best choice for a cord blood unit(s) does not meet all FDA standards, but do meet standards set by the National Marrow Donor Program (NMDP) on this study, and to assess how well and how quickly blood counts return to normal after transplant in recipients on this study.
The purpose of this study is to find out if and how the study drug controls your cancer and how your cancer cells respond to the study drug, the side effects of the study drug, how long the study drug stays in your body, and to evaluate whether special blood tests can predict how effective the study drug will be for you.
The purpose of this research study is to determine how the drug, arsenic trioxide, is used and processed by the body. The study will also look at the long term effects of arsenic trioxide on the body.
This research study is testing an experimental drug called ABT-199 when used in combination with rituximab. Experimental means the study drug has not been approved by the United States Food and Drug Administration (FDA) for use except in research.
Rituximab is and FDA approved drug for treating some cancers. This drug is commonly used in treating leukemia and lymphoma.
ABT-199 inhibits or blocks proteins called Bcl-2 that may help tumors become resistant to chemotherapy and rituximab. This study will look to see if ABT-199 taken together with rituximab may help rituximab to work better. The combination of ABT-199 and rituximab has not been tested or approved by the FDA. This will be the first research study to test the combination. ABT-199 taken together with rituximab may not work better than rituximab alone.
The purpose is to study the following:
- The safety and effects of ABT-199 in combination with rituximab when given to subjects with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Test increasing doses of ABT-199 in combination with rituximab
- Find out how the body absorbs and handles the combination of drugs
- Substances found in the blood and tissue (biomarkers) that may indicate the effects or progress of the disease and the activity of ABT-199
The purpose of this research study is:
- To find out whether dalantercept and axitinib in combination can stop Renal Cell Carcinoma(RCC) from growing, or prevent it from growing as fast as it would without dalantercept.
- To evaluate whether dalantercept in combination with axitinib is safe for subjects with RCC.
- To measure the amount of dalantercept and/or axitinib in the blood of participating research subjects.
- To find out if dalantercept and/or axitinib have an effect on biomarkers (molecules that indicate whether and how well people respond to these drugs) in the blood and/or tissue.
This study is testing an experimental drug called PEGPH20. Experimental means the United States Food and Drug Administration (FDA) has not approved PEGPH20 for use except in research studies like this.
There are two parts to this study. The purpose of both parts is to evaluate PEGPH20 in combination with two chemotherapy drugs. These drugs are a standard dose of gemcitabine plus a dose of nab-paclitaxel that has been tested in pancreatic cancer patients. This combination will be compared to gemcitabine and nab-paclitaxel alone (without PEGPH20). The first part (run-in phase) will study the safety and tolerability of these combinations. The second part (phase 2) will study the safety and efficacy (how well the drug works) of these combinations.
This research study is evaluating an experimental drug called GS-1101 (also known as CAL-101) as a possible treatment for chronic lymphocytic leukemia. Experimental means GS-1101 has not been approved by the US Food and Drug Administration (FDA) for use except in research. All cells in the body receive signals to grow, but sometimes these signals get out of control, causing too much cell growth. When the growth of lymphocytes (a type of white blood cell) gets out of control, cancers like CLL can develop. Drugs like GS-1101 block CLL cells from growing. GS-1101 may also help control the disease, but this is not known.
The purpose of this study is to provide more information about whether GS-1101 is effective and safe for treating people with CLL, particularly in subjects who have medical problems that might make it difficult for them to receive chemotherapy for CLL. The research from this study will provide information on if GS-1101 helps people when given alone and whether a change in dose may help people who have CLL that appears to be resistant to the study drug. This study will also give information on whether people show any medical problems when they take the drug for a long period of time.
In past research studies, over 100 subjects with CLL have received GS-1101, either alone or in combination with other anticancer drugs. In those studies, GS-1101 may have helped to control the CLL in some of the subjects when given together with another drug (rituximab) or when given alone.
Human papilloma virus (HPV) is frequently found within tumor cells removed from patients diagnosed with oropharynx cancer. Tumors which do not contain HPV virus (termed “HPV-negative”) are not cured as frequently by radiation therapy. Tumors which do contain HPV in patients who have a history of cigarette smoking also are not cured as frequently by radiation.
One way to potentially overcome this challenge is to safely deliver a more intense dose of radiation treatment to the tumor. The standard way to deliver radiation, termed Intensity Modulated Radiotherapy (IMRT), can protect normal tissues near tumors to a certain degree, but not completely. Stereotactic radiosurgery (SRS) is a technique which can deliver radiation more precisely.
This trial will test the safety of treating HPV-unassociated oropharynx tumors to higher radiation doses with SRS (termed a “boost”) after a standard course of IMRT has been given. In addition, we want to see if magnetic resonance imaging (MRI) scanning can detect treatment response in oropharynx tumors earlier than with standard tests.
The purpose of this study is to determine the safety of a drug called lenalidomide, at different doses, when it is given during radiation therapy and for up to 2 years afterwards. Researchers also want to find out what effects, good or bad, it has on the patient and their brain tumor.
In all patients with multiple myeloma treated with autologous stem cell transplant followed by low dose lenalidomide maintenance, the disease will return. The purpose of this research study is to determine whether the disease will get better if treated with higher doses of lenalidomide even if the disease returned while taking low doses of lenalidomide.
The purpose of this study is to find out what effects, good and/or bad, treatment with vemurafenib (also known as Zelboraf) has on hairy cell leukemia. Specifically, we want to know how well vemurafenib eliminates leukemia from the blood.
One purpose of this study is to test the safety and tolerability of the research study drug, sitagliptin compared to placebo when added to extended-release metformin (metformin XR) in children 10-17 years of age with type 2 diabetes. Sitagliptin plus metformin XR will be given together as a single tablet in this study. Another purpose is to assess the effect of MK-0431A XR (sitagliptin and metformin XR), compared to placebo and metformin XR, on hemoglobin A1C in children 10-17 years old after taking it for 20 weeks of study drug regimen. The A1C test is used to measure blood sugar control over the previous 2 to 3 months.
The purpose of this study is to compare the effects of dose-escalated radiation therapy (radiation therapy using higher doses than is commonly done) with or without hormone therapy (treatment that prevents cancer cells from getting the hormones they need to grow) on prostate cancer. Prior studies have suggested possible advantages to the administration of hormonal therapy with radiation. However, those studies were performed with radiation techniques that do not match those commonly used in clinical practice today (that is, dose-escalated radiotherapy. Therefore, this study will be testing to see if similar benefits for hormonal therapy are seen when used with current radiation techniques.
In current clinical practice, either radiation therapy alone (Group 1 in this study) or radiation therapy combined with hormone therapy (Group 2 in this study) would be considered an acceptable standard treatment for patients with a newly diagnosed intermediate risk prostate cancer.
The researchers doing this study want to see if using hormonal therapy with radiation will increase chances of curing prostate cancer.
This study is being done to evaluate the effects (good and bad) of different chemotherapy treatments. One of the common combinations of chemotherapy drugs used to treat cancer of the colon which has been surgically removed but has spread to lymph nodes includes 5-fluorouracil (also called 5-FU), leucovorin, and oxaliplatin, and is also called “FOLFOX”. At the present time, the Food and Drug Administration (FDA) has approved each of these drugs as treatment for colon cancer. FOLFOX is a standard treatment used to prevent colon cancer from coming back (recurrence).
This study will evaluate the effects (good and bad) of a drug given by mouth called celecoxib when given in combination with FOLFOX chemotherapy. Celecoxib is approved by the FDA to treat arthritis and some other painful conditions. The addition of celecoxib to FOLFOX chemotherapy Is considered investigational. One of the purposes of this study is to determine if giving patients celecoxib (by mouth) and chemotherapy decreases the risk of colon cancer recurrence.
The study will also look at whether receiving FOLFOX chemotherapy for 6 treatments (12 weeks) is as good as 12 treatments (24 weeks) in preventing the colon cancer from coming back. Currently, the standard of care for this stage of colon cancer is 12 treatments with FOLFOX. That was the number of treatments tested in previous research studies. However, it is not known if fewer treatments would be as helpful in preventing the cancer from coming back. This trial will explore whether 6 treatments work as well as 12 treatments and whether side effects can be reduced with fewer treatments.
The purpose of this study is to see if standard treatment plus additional chemotherapy reduces the risk of tumor recurrence and improves overall survival compared to standard treatment alone. Standard treatment is radiation therapy combined with the chemotherapy drug cisplatin (chemo-radiation.) The experimental part of this study will combine the standard treatment with additional experimental chemotherapy agents carboplatin and paclitaxel. Carboplatin and paclitaxel are FDA approved chemotherapy agents, but they are not used in this way.
The purpose of this study is to test the safety and tolerability (the level of side effects) of the research study drug, sitagliptin, in children 10-17 years old. Researchers will assess the effect of sitagliptin compared to placebo on A1C after taking it for 16 weeks. The A1C test measures blood glucose control for the past 2 to 3 months. Researchers will also assess the effect of sitagliptin after taking it for 54 weeks.
The Oncotype DX test is a commercially available test that is already being used to assess the risk that breast cancer will come back after surgery. The test looks at multiple genes related to breast cancer. The combination of the test results produces a score that is useful in guiding treatment choices for patients with node-negative breast cancer. The higher the score is, the more likely that the patient’s breast cancer will come back after surgery. The performance of the test is not part of the research question in this study.
In the first part of this experimental study, breast cancer tissue will be sent for Oncotype DX Recurrence Score testing to find out if patients may be eligible to participate in the next part of the study.
The purpose of this research study is to find out if the Oncotype DX Recurrence Score can help decide whether patients should receive chemotherapy or not. This study is being done in patients with lower Recurrence Scores (25 or less).
Currently, most women who have hormone-responsive breast cancer with 1-3 positive lymph nodes, and a Recurrence Score of 25 or less are treated with endocrine therapy (treatment that works with hormones). Many women also receive chemotherapy. No one really knows which patients with lower Recurrence Scores need to get chemotherapy. Some women may be getting chemotherapy who do not need it. These women may be exposed to side effects of their treatment that are not a necessary risk in relation to benefit they receive.
If the results of the study show that the benefit for getting chemotherapy is dependent on the Recurrence Score, the study should be able to identify a Recurrence Score level where chemotherapy should be considered (and a recurrence score level where chemotherapy may not be needed).